Skip to content
Search

Latest Stories

H2-antagonists face supply disruption due to spike in demand

The Department of Health and Social Care (DH) has issued a medicine supply disruption notice for H2-antagonists- Cimetidine, Famotidine, and Nizatidine.

Suppliers of Cimetidine, Famotidine and Nizatidine have reported an increase in demand, which has contributed to short term shortages of Cimetidine 200mg tablets, Famotidine 20mg tablets, and Nizatidine 150mg and 300mg tablets, the DH said.


Here is the list of H2-antagonists which are facing supply disruption:

ProductSupplierCurrent Stock PositionAnticipated Resupply dateDetail
Famotidine 20mg tabletsTilomed LaboratoriesIn stockn/a
Teva UKOut of stockMay 2021
Famotidine 40mg tabletsTilomed LaboratoriesIn stockn/a
Teva UKOut of stockJune 2021
Cimetidine 200mg tabletsEnnogen PharmaOut of stockJune 2021Unlicensed supplies have been sourced
MedreichOut of stockto be confirmed
Cimetidine 400mg tabletsEnnogen PharmaOut of stockJune 2021
MedreichOut of stockto be confirmed
Cimetidine 800mg tabletsEnnogen PharmaOut of stockJune 2021
MedreichOut of stockto be confirmed
Cimetidine 200mg/5ml oral solutionRosemont PharmaceuticalsIn stockw/c 5 April 2021
Cimetidine (Tagamet) 200mg/5ml syrupEssential PharmaIn stockn/a
Nizatidine 150mg capsulesViatris (Mylan)Out of stockto be confirmed
MedreichOut of stockto be confirmed
RelonchemIn stockn/a
Nizatidine 300mg capsules Viatris (Mylan)Out of stockto be confirmed
MedreichOut of stockto be confirmed
RelonchemIn stockn/a

Target Healthcare, Durbin PLC, Mawdsley’s Unlicensed, and Alium Medical have informed that they can source unlicensed cimetidine 200mg, 400mg and 800mg tablets.

Ennogen has said that it can source unlicensed cimetidine 200mg and 400mg tablets.

The drug manufacturer Smartway Pharma and Waymade PLC have also informed that they are able to source unlicensed cimetidine tablets.

If there is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems an EPS prescription for unlicensed Cimetidine (strength) tablets cannot be issued.

Where a prescriber wishes to prescribe an unlicensed import, an FP10 paper prescription should be issued as ‘Cimetidine (strength) tablets (Special Order)‘ and endorsed by the pharmacy as a non-Part VIIIB special.

More For You

NICE calls for annual BMI checks for adults with long-term conditions

Annual BMI measurements create early intervention opportunities for weight management

Getty Images

NICE seeks feedback on annual BMI checks for adults with long-term conditions

The National Institute for Health and Care Excellence (NICE) has published a draft quality standard recommending annual Body mass index (BMI) and waist-to-height measurements for adults with long-term conditions to help prevent weight-related complications.

A consultation has been launched to gather feedback from healthcare professionals and commissioners on the feasibility of implementing these proposals within the NHS.

Keep ReadingShow less
Medicine shortages: Penny-pinching costs taxpayers more, warns CCA

Pharmacies are forced to dispense medicines at a loss or face stock shortages.

Getty Images

Government’s penny-pinching approach driving medicine shortages, CCA warns

The Company Chemists’ Association (CCA) has warned the government's longstanding drive to save pennies on the medicines bill is leading to avoidable medicine shortages, ultimately costing taxpayers more.

In a newly released paper, the CCA highlighted how the government has squeezed the price it is willing to pay for many medicines, making the UK a less attractive market for pharmaceutical manufacturers and suppliers.

Keep ReadingShow less
Morrison: Pharmacy contract news

Janet Morrison

Morrison: Pharmacy contract news “before the start of the financial year”


Community pharmacies will get clarity over a new funding contract before the start of the financial year, according to Community Pharmacy England (CPE) chief executive Janet Morrison.

Keep ReadingShow less
Amanda Pritchard appointed chief executive of Guy's and St Thomas'

Amanda Pritchard appointed chief executive of Guy's and St Thomas'

Amanda Pritchard appointed chief executive of Guy's and St Thomas'

Amanda Pritchard, who is set to step down as NHS England chief in April, has been appointed as the next chief executive of Guy’s and St Thomas’ NHS Foundation Trust.

Pritchard previously led the Trust from October 2015 to August 2019 before moving to NHS England, where she later became its first female chief executive in August 2021.

Keep ReadingShow less
Confirm Pharmacy First Funding beyond April- Helen Morgan MP urges health secretary

North Shropshire MP Helen Morgan

Helen Morgan MP calls on Wes Streeting to clarify Pharmacy First’s future

Liberal Democrat health and care spokesperson Helen Morgan has urged the government to provide clarity on the future of Pharmacy First and confirm continued funding beyond April.

In a letter to health secretary Wes Streeting, the North Shropshire MP expressed deep concern over the uncertainty surrounding the initiative, which plays a crucial role in shifting healthcare services into communities.

Keep ReadingShow less